Cognitive Stack

The Cognitive Stack pairs two synthetic heptapeptides that emerged from the same Russian neuroscience tradition yet operate through strikingly different biological mechanisms. Selank — a tuftsin analog — research suggests it may reduce anxiety and neuroinflammation through GABAergic modulation and enkephalinase inhibition [PMID: 21833148]. Semax — an ACTH(4-10) fragment — studies indicate it may enhance neuroplasticity by upregulating brain-derived neurotrophic factor (BDNF) and activating its TrkB receptor system [PMID: 16996037].

What makes this combination particularly interesting is that the two peptides appear to target cognition from opposite ends of the neurological spectrum. One addresses the anxiety and inflammatory burden that degrades cognitive performance. The other directly promotes the neuroplastic machinery that underlies learning and memory. An fMRI study examining both peptides in 52 healthy participants found both general and specific effects on functional connectivity in brain regions associated with emotion and cognition — the first direct evidence that these compounds may produce complementary neural effects when studied in the same experimental framework [PMID: 32342318].

Both compounds are classified as research peptides with evidence drawn primarily from clinical studies conducted in Russia and preclinical animal models. No human clinical trial has established efficacy or safety for this specific combination. The information on this page reflects the published scientific literature as a resource for researchers — not guidance for human use, medical treatment, or diagnosis.

The scientific rationale for combining Selank and Semax rests on their apparently non-overlapping mechanisms acting on complementary aspects of cognitive function.

Selank modulates the brain's stress and inflammatory systems through multiple pathways. Research indicates it may inhibit enkephalinase, an enzyme that breaks down endogenous opioid peptides, potentially enhancing the body's natural calming mechanisms [PMID: 21833148]. Studies also suggest it modulates pro-inflammatory cytokines — specifically IL-6 and TNF-alpha — which are known to impair cognitive function when chronically elevated [PMID: 21493795]. Its interaction with the GABAergic system is believed to produce anxiolytic effects that have been documented in clinical settings [PMID: 21833148].

Semax operates through entirely different molecular targets. Preclinical studies demonstrate that a single dose can increase BDNF protein levels by up to 1.4-fold and TrkB receptor phosphorylation by 1.6-fold in the hippocampus — the brain region most critical for learning and memory [PMID: 16996037]. Additional research suggests it modulates serotonin and dopamine neurotransmitter systems, which are central to attention, motivation, and executive function [PMID: 25313017].

The complementarity here is mechanistically compelling. Chronic stress and neuroinflammation are well-established suppressors of BDNF expression — meaning that Selank's anxiolytic and anti-inflammatory activity may create more favorable conditions for Semax's neuroplastic effects to operate. A 2020 functional connectivity study directly compared both peptides in healthy volunteers using resting-state fMRI, observing distinct yet overlapping effects on amygdala-temporal cortex connectivity — brain regions involved in emotional processing and memory consolidation [PMID: 32342318]. This study provided the first neuroimaging evidence that both compounds can be studied simultaneously, with each producing identifiable neural signatures.

No clinical trial has tested this specific combination in humans, and the synergy rationale is extrapolated from independent studies on each compound plus the single comparative fMRI study. Researchers should treat the evidence as exploratory and approach any protocol design with careful documentation.

A practical advantage of this stack is that both peptides share the same preferred administration route: intranasal delivery. This simplifies protocol design compared to stacks requiring different routes — both compounds can be administered as nasal sprays, which research suggests improves central nervous system access while avoiding first-pass metabolism [PMID: 21493795] [PMID: 25313017].

The two compounds differ, however, in their studied dosing parameters. Selank clinical studies for anxiety have used intranasal doses of 0.15–0.3 mg per day [PMID: 21493795], while Semax research for cognitive endpoints has examined doses ranging from 0.1–1.0 mg per day [PMID: 25313017]. This means that while the delivery method is identical, the doses for each compound require independent calibration rather than matching.

Both peptides have short half-lives measured in minutes, which has implications for timing and frequency. Consistent daily scheduling is generally considered important in research protocols to maintain stable signaling exposure. Some anecdotal research literature describes concurrent daily administration of both compounds, while others suggest sequential timing aligned with specific research goals — for instance, Selank in the evening to study its effects on sleep-related recovery, and Semax in the morning to study its effects on daytime cognitive performance.

No standardized combined protocol exists. All available information reflects either independent clinical studies on each compound or anecdotal research use. All dosing information should be treated as preliminary, and researchers should maintain careful documentation of any combined protocol.